Skip to main content

Craves Fred B's Form 4 filing

Madrigal Pharmaceuticals, Inc. (MDGL) · filed Mar 14, 2025

Accession no.
0001628280-25-012826
Filed
Mar 14, 2025
Trade date
Mar 12-13, 2025
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 16 non-derivative transactions and 3 derivative transactions. Open-market sales total $5.08M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Craves Fred BCIK 0001014095Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 12, 2025Common StockMOption exerciseAcquired+1,728$65.06+$112,423.68351,804Direct
Mar 12, 2025Common StockMOption exerciseAcquired+6,000$111.06+$666,360357,804Direct
Mar 12, 2025Common StockSSaleDisposed−1,587$330.54F1−$524,566.98356,217Direct
Mar 12, 2025Common StockSSaleDisposed−2,759$331.36F2−$914,222.24353,458Direct
Mar 12, 2025Common StockSSaleDisposed−2,382$332.38F3−$791,729.16351,076Direct
Mar 12, 2025Common StockSSaleDisposed−800$333.66F4−$266,928350,276Direct
Mar 12, 2025Common StockSSaleDisposed−200$334.97F5−$66,994350,076Direct
Mar 13, 2025Common StockMOption exerciseAcquired+7,742$65.06+$503,694.52357,818Direct
Mar 13, 2025Common StockSSaleDisposed−1,951$322.45F6−$629,099.95355,867Direct
Mar 13, 2025Common StockSSaleDisposed−1,649$323.47F7−$533,402.03354,218Direct
Mar 13, 2025Common StockSSaleDisposed−900$324.69F8−$292,221353,318Direct
Mar 13, 2025Common StockSSaleDisposed−800$325.63F9−$260,504352,518Direct
Mar 13, 2025Common StockSSaleDisposed−1,000$327.63F10−$327,630351,518Direct
Mar 13, 2025Common StockSSaleDisposed−400$328.68F11−$131,472351,118Direct
Mar 13, 2025Common StockSSaleDisposed−967$329.86F12−$318,974.62350,151Direct
Mar 13, 2025Common StockSSaleDisposed−75$330.23−$24,767.25350,076Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 12, 2025Common StockMOption exerciseDisposed−1,728$0.00$07,742Direct
Mar 12, 2025Common StockMOption exerciseDisposed−6,000$0.00$00Direct
Mar 13, 2025Common StockMOption exerciseDisposed−7,742$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $330.00 to $330.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

Referenced by the price of 1 transaction in Table I.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $331.00 to $331.89, inclusive.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $332.01 to $332.88, inclusive.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $333.39 to $333.89, inclusive.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $334.95 to $334.99, inclusive.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $322.02 to $323.00, inclusive.

Referenced by the price of 1 transaction in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.02 to $323.97, inclusive.

Referenced by the price of 1 transaction in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $324.16 to $324.84, inclusive.

Referenced by the price of 1 transaction in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $325.34 to $325.955, inclusive.

Referenced by the price of 1 transaction in Table I.

F10

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $327.19 to $328.18, inclusive.

Referenced by the price of 1 transaction in Table I.

F11

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $328.20 to $329.165, inclusive.

Referenced by the price of 1 transaction in Table I.

F12

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $329.22 to $330.20, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)